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The Malaria Policy Advisory Committee to the World Health Organization met in Geneva, Switzerland from 13 to 15
March, 2013. This article provides a summary of the discussions, conclusions and recommendations from that
meeting.
Meeting sessions included: a review of the efficacy of artemisinin-based combination therapy in Guyana and
Suriname; the outcomes from a consultation on non-malaria febrile illness; the outcomes from the second meeting
of the Evidence Review Group on malaria burden estimation; an update on the review of the WHO Guidelines for
the Treatment of Malaria; an update regarding progress on the constitution of the vector control Technical Expert
Group; updates on the RTS, S/AS01 vaccine and the malaria vaccine technology roadmap; financing and resource
allocation for malaria control; malaria surveillance and the need for a surveillance, monitoring and evaluation
Technical Expert Group; criteria and classification related to malaria elimination; the next meeting of the Evidence
Review Group on Intermittent Preventive Treatment in pregnancy; an update on the soon-to-be launched
Elimination Scenario Planning Tool; and an update on the process for the Global Technical Strategy for Malaria
Control and Elimination (2016–2025).
Policy statements, position statements, and guidelines that arise from the MPAC meeting conclusions and
recommendations will be formally issued and disseminated to World Health Organization Member States by the
World Health Organization Global Malaria Programme.
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The Malaria Policy Advisory Committee (MPAC) to
the WHO met from 13 to 15 March 2013 in Geneva,
Switzerland, following its meetings in February and
September 2012 [1,2]. This article provides a summary
of the discussions, conclusions and recommendations
from that meetinga as part of the recently established
Malaria Journal thematic series “WHO global malaria
recommendations” [3].
The following sections of this article provide details
and references for the background documents presented
at the open meeting sessions of the committee on: a re-
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from a consultation on non-malaria febrile illness; the
outcomes from the second meeting of the Evidence Re-
view Group (ERG) on malaria burden estimation; an up-
date on the review of the WHO Guidelines for the
Treatment of Malaria; an update from the newly cons-
tituted vector control Technical Expert Group (TEG);
updates on the RTS,S/AS01 vaccine and the malaria vac-
cine technology roadmap; financing and resource alloca-
tion for malaria control; malaria surveillance and the
need for a surveillance, monitoring and evaluation TEG;
criteria and classification related to malaria elimination;
the next meeting of the ERG on Intermittent Preventive
Treatment in pregnancy (IPTp); an update on the soon-
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for Malaria Control and Elimination (2016–2025).
The MPAC discussion and recommendations related
to these topics, which took place partially in closed ses-
sion, are also included. MPAC decisions are reached by
consensus [4]. The next meeting of the MPAC will be 11
to 13 September 2013 [5].
Report from the WHO global malaria programme
The Director of the WHO Global Malaria Programme
(WHO-GMP) updated MPAC members on progress with
recommendations from their last meeting [6], in particular
highlights from the World Malaria Report (WMR) 2012
[7] and updates from the WHO Regional Offices.
The presentation, on behalf of the Global Malaria
Team (WHO-GMP staff and the WHO Regional Malaria
Advisors) highlighted the urgent need to improve sur-
veillance systems, which are essential for targeting ma-
laria control at national and subnational levels. Figures
showed that the higher the malaria burden in countries,
the lower the proportion of cases that are captured by
surveillance systems, and the less likely that trends can
be reliably assessed. In other words, malaria surveillance
systems are weakest where the malaria burden is grea-
test – the 58 countries in which it is possible to assess
trends using data from routine health information systems
account for only 15% of the global malaria burden.
Updates were also provided on the global strategic
plan for Plasmodium vivax control and elimination, due
for completion by 2015, and the Malaria Situation
Room, a collaborative effort, led by the Roll Back Ma-
laria (RBM) Partnership secretariat and WHO, with
support from the African Leaders Malaria Alliance, the
International Federation of the Red Cross and Red Cres-
cent Societies, and the Office of the UN Secretary Ge-
neral’s Special Envoy for Malaria and Financing of the
Health Millennium Development Goals (MDGs), to
track financial flow, commodities, intervention coverage
and impact to identify and alleviate bottlenecks. Initially,
the Malaria Situation Room will focus on the ten highest
burden countries in Africa, as they account for 70% of
regional and 56% of the global malaria burden.
In addition, updates were provided on: the soon-to-
be-implemented Rapid Access Expansion (RAcE) 2015
programme [8], which will provide support to catalyse
the scale-up of integrated community case management
of malaria, pneumonia and diarrhoeal disease (iCCM) in
five African countries as an integral part of government
health services; seasonal malaria chemoprevention (SMC)
[9], for which an implementation manual was launched
and a training workshop conducted at the end of 2012;
the opening of a regional hub in Cambodia as part of
the emergency response to artemisinin resistance in the
Greater Mekong sub-Region [10], which was endorsed bycountries in February 2013 and launched on World
Malaria Day; the publication of the third edition of the
handbook for the Management of Severe Malaria [11] in
early 2013; the publication of four case studies on malaria
elimination in October 2012 [12-15], with six more due to
be launched in 2013 (Turkey, Philippines, Malaysia, La
Reunion, Tunisia, Bhutan) to help national malaria control
programmes and other partners contemplating elimi-
nation have a better understanding of process involved;
and key features of the new funding model at the Global
Fund [16].
MPAC commended the work of WHO-GMP and the
Regional Offices in helping countries to monitor and
reduce their malaria burden. It also highlighted the
importance of increasing support to malaria-endemic
countries to build human resource capacity to manage
malaria programmes, undertake operational research
and implement policy recommendations at all levels of
the health care system.
Drug resistance
Therapeutic efficacy monitoring is an essential step in
preventing the emergence of artemisinin resistance [17].
When it last met in June 2012 [18], and during its up-
date to MPAC in September 2012 [19], the drug resis-
tance and containment TEG (DRC TEG) recommended
that, although there was at the time no evidence of ar-
temisinin resistance outside the Greater Mekong sub-
Region, nonetheless surveillance on ACT efficacy outside
the sub-Region should continue and be intensified. It en-
couraged consultation with the DRC TEG by WHO-GMP
whenever new data raise concerns.
The DRC TEG and WHO-GMP reported that in early
2013, preliminary results from therapeutic efficacy stu-
dies conducted in Suriname and Guyana raised a signal
that artemisinin resistance may be emerging in South
America in certain areas with a high number of migrants
[20,21]. An informal consultation on the emergence of
artemisinin resistance in South America, attended by rep-
resentatives from the Ministries of Health of Suriname
and Guyana, the US Centers for Disease Control and Pre-
vention, the US Agency for International Development,
WHO, and the chair of the DRC TEG, was held in
Washington DC in February 2013 to review the most re-
cent data from Suriname and Guyana.
Given reports of reduced parasite clearance on day
three, which is an indication of possible emerging resis-
tance, representatives at this consultation meeting ag-
reed that activities to contain artemisinin resistance, as
outlined in the Global Plan for Artemisinin Resistance
Containment (GPARC) [17], should be initiated. How-
ever, they also agreed that confirmatory studies should
be conducted in Suriname and Guyana as soon as pos-
sible. This conclusion was fully supported by MPAC,
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Suriname and Guyana studies appeared to be variable.
MPAC concluded that it cannot be determined if the
signal of possible resistance is real or an artifact resulting
from technical problems.
A communication regarding the findings from Suriname
and Guyana and short-term actions has been issued by
the WHO-PAHO office [22]. If the possibility of the emer-
gence of artemisinin resistance is confirmed by further
studies or additional data, various stakeholders, including
neighbouring countries, donors and technical partners,
will be notified of the data and their implications.
MPAC advised that although many countries in South
America have managed to dramatically reduce the num-
ber of malaria cases, the findings from Suriname and
Guyana highlight the need for all endemic countries to
conduct routine monitoring of therapeutic efficacy of
anti-malarial drugs. It also recommended that the DRC
TEG increase its membership to include a national mal-
aria control programme (NMCP) representative from
South America, in addition to two representatives from
Southeast Asia.
Non-malaria febrile illness
Increased diagnostic testing of malaria prior to treat-
ment, paired with decreasing malaria transmission in
many areas, has resulted in an increased proportion of
febrile patients being diagnosed as not having malaria
[23]. However, following the longstanding practice of
treating malaria based on the presence of fever alone,
health workers may ignore negative test results and still
treat the patient with an anti-malarial. This negates the
clinical benefits of diagnostic confirmation, wastes valu-
able anti-malarial drugs, and potentially increases the
drug pressure on Plasmodium parasites. These problems
are exacerbated by the absence of guidance and medicines
for the management of non-malaria febrile illnesses.
To help address the lack of guidance, WHO-GMP and
the Special Programme for Research and Training in
Tropical Diseases (TDR) convened an informal consult-
ation in January 2013 to: (a) review existing evidence and
guidance on the management of malaria and non-malaria
fevers at primary care and community levels; (b) provide
practical recommendations and operational tools based
on research findings and successful country experiences
for the implementation of integrated management of fe-
vers at peripheral health facility and community level; and,
(c) identify and discuss major research gaps [24].
The main conclusions and recommendations from this
meeting are:
1. Malaria diagnostic testing and treatment should be
deployed as part of programmes promoting the
integrated management of fevers.2. Evidence and lessons learned from implementation
studies should be taken into account when scaling-
up iCCM.
3. The key elements of the generic iCCM algorithm
should not be modified when adopted and
implemented in different countries.
4. iCCM programmes should be implemented together
with strengthening quality of care in health facilities.
5. Programmes aimed at improving the quality of care
of malaria case management in the private sector
should also cover the diagnosis and treatment of
common non-malaria causes of fever.
6. More studies on aetiologies of fevers need to be
undertaken at different levels of health care and in
different epidemiological settings, seasons and age
groups.
7. Research on new strategies for effective diagnostic
testing and treatment of febrile illness should be
encouraged, using clinical outcomes as primary
study endpoints, in order to modify or expand the
diseases which are being targeted by the current
WHO algorithms based on health care needs.
The MPAC endorsed the conclusions of the informal
consultation and encouraged global malaria control part-
ners to adopt the meeting recommendations as
appropriate.
Malaria burden estimation
The ERG on malaria burden estimation (ERG MBE) met
for the second of three planned meetings from 22 to 24
January, 2013 to: (a) review current methods in malaria
morbidity and mortality estimation with the partici-
pation of the experts involved in the development of
currently used methods; (b) achieve consensus on the
methods that should be used in the future by WHO;
and, (c) identify research that could facilitate the recon-
ciliation of different methodologies and results [25].
As part of its update to MPAC [26], the ERG re-
commended that for 2013 morbidity estimates, WHO
should continue to estimate cases as it does currently,
but should vary/test assumptions regarding the value of
insecticide-treated net (ITN) effectiveness and investi-
gate malaria positivity among febrile children seeking
care versus those not seeking care. For 2014 and beyond,
in sub-Saharan Africa, it recommended that WHO de-
rive case estimates based on a time-series of Plasmo-
dium falciparum parasite rate (PfPR) assembled by the
Malaria Atlas Project (MAP) and a refined model of the
relationship between prevalence and incidence (includ-
ing survey data, seasonality information and new covari-
ates). For outside of Africa and in African countries with
robust surveillance data, the ERG MBE recommended
that morbidity estimates should be based on reported
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systems become stronger, more countries will be able to
use the Health Management Information System (HMIS).
It also recommended that point estimates and uncer-
tainty ranges should always be presented together, and
country consultations should remain integral to the
process in order to understand data quality and anomal-
ies and to validate results. The development of a more
user-friendly cartographic methodology should also be
explored [25].
For malaria mortality estimation, the ERG MBE re-
commended that for 2013, WHO should estimate ma-
laria deaths as it does currently, but should also derive
and apply a case fatality rate for P. vivax in order to esti-
mate these deaths. It has not yet reached a conclusion
on what the recommended approach for mortality esti-
mates should be in 2014 and beyond, as it found that
there are substantial limitations in all the current me-
thods. Similar to its recommendations for morbidity
estimates, the ERG MBE recommended that point es-
timates and uncertainty ranges for malaria mortality
should always be presented together and country consul-
tations should be an integral part of the estimation
process [25].
The ERG MBE had several recommendations to im-
prove the science of malaria burden estimation. For ex-
ample, for morbidity estimates, it suggested exploring
methods of collecting additional prevalence data, e.g.,
through rapid diagnostic tests (RDTs) at antenatal visits,
Expanded Programme on Immunization (EPI) visits, or
during school deworming campaigns. For improving
mortality estimates, suggestions included novel research
to examine age patterns of malaria deaths and the rela-
tionship between PfPR and mortality, e.g., case–control
studies comparing parasite prevalence in those dying of
any cause and controls, and prospective cohort studies
of all-cause mortality in relation to malaria exposure. To
explore reasons for differing results, the ERG MBE sug-
gested that the Child Health Epidemiology Reference
Group (CHERG) should rerun its model using less re-
strictive verbal autopsy (VA) inclusion criteria, and that
the Institute for Health Metrics and Evaluation (IHME)
should rerun its model without redistribution of un-
assigned VA deaths. The ERG MBE asked MPAC to
consider the need for a TEG that could provide ongoing
guidance to evaluate new estimation methods for both
morbidity and mortality as new studies and methods are
developed [26]. This was addressed as an agenda item
later in the meeting.
The MPAC concluded that while there seems to be a
reasonable way forward with respect to the estimation of
malaria case numbers, which WHO-GMP will adopt for
the next WMR and onwards, the most appropriate me-
thod for estimating malaria deaths, particularly amongadults for whom VA remains a very crude estimation
tool, is unclear. Following an upcoming teleconference,
the ERG MBE will decide on the necessity for, and the
timing of, its final meeting prior to the next MPAC
meeting in September 2013. Several partners, including
INDEPTH, expressed a willingness to assist WHO-GMP
in continuing to improve malaria burden estimation.
WHO guidelines for the treatment of malaria
The WHO Guidelines for the Treatment of Malaria
(MTGs) provides comprehensive evidence-based guide-
lines for the formulation of policies and protocols for
the treatment of malaria globally; the document was last
revised in 2010. The MPAC, at its last meeting, endorsed
the plan presented by the Chemotherapy TEG to update
the MTGs and for WHO-GMP to publish a third edi-
tion. The sub-committee of the Chemotherapy TEG
tasked with developing the scope of work for the next
edition of the MTGs met in Geneva from 25 to 26
February, 2013 and consensus was reached on the pro-
posed revisions and updates for the third edition of
the MTGs [27].
In its update to MPAC [28], the Chemotherapy TEG
reported that it would conduct a comprehensive review
of existing recommendations in light of any new evi-
dence that might affect each recommendation in its
totality, or with regard to the strength of the recommen-
dation. A new section will be included to guide the use
of anti-malarials in the prevention of malaria, i.e., inter-
mittent preventive treatment, seasonal malaria chemo-
prevention, and chemoprophylaxis in travellers. This
addition was welcomed by MPAC, which also suggested
that it might be useful to receive feedback on the MTGs
content from current endusers.
MPAC endorsed the timeline proposed – systematic
review completion by the end of 2013 with publication
of the revised MTGs in mid-2014 – but added that these
were ambitious targets. The major rate-limiting step will
be the availability of evidence in a format suitable for
systematic review to which the grades of recommenda-
tion assessment, development and evaluation (GRADE)
methodology, which is the system used by the WHO
Guidelines Review Committee, can be applied. The
chemotherapy TEG will update MPAC on progress with
the systematic reviews at its next meeting in September
2013.
Malaria vector control
At its last meeting in September 2012, MPAC endorsed
the establishment of a vector control TEG (VC TEG) on
malaria vector control to review and make recommen-
dations on the use and appropriate mix of malaria vector
control interventions for particular situations, inclu-
ding: (a) the adoption of new forms of vector control
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the newly established Vector Control Advisory Group
(VCAG); (b) the formulation of evidence-based norms,
standards and guidelines for the implementation and
management of malaria vector control; (c) policy issues re-
lated to building capacity for entomological monitoring
and optimization of vector control investments; and, (d)
identifying gaps in evidence and specific areas of research
to improve the management and implementation of mal-
aria vector control.
Following an open call for curriculum vitae (CV) from
experts interested in serving on either the VC TEG or
the VCAG, a total of 147 applications were received and
reviewed by a panel that included external experts.
VCAG, focused on vector control tools, including those
for other vector-borne diseases such as dengue, will be
jointly managed by WHO-GMP and the WHO Neglec-
ted Tropical Disease Department (WHO-NTD). The VC
TEG, focused on malaria vector control strategies, is
managed by WHO-GMP and reports to the MPAC.
Members for both groups have now been selected and
the groups have been formally constituted [29].
In its update to MPAC [30], the VC TEG, which plans
to meet for the first time in July 2013, outlined its work
plan, which includes the following outputs, which will
be presented for approval at the next MPAC meeting in
September 2013: (a) a position statement on methods
for maintaining coverage with long-lasting insecticidal
nets (LLINs); (b) technical guidance for countries and
partners on how to estimate the survival of LLINs from
field data on durability; and, (c) technical guidance for
countries on how to prioritize malaria vector control
interventions when faced with constrained or unstable
resources. In addition, the VC TEG plans to draft a tech-
nical paper on capacity building for malaria vector con-
trol as part of its work plan for 2014.
MPAC welcomed the first three major tasks of the
new VC TEG, which will provide urgently needed guid-
ance to countries on malaria vector control, particularly
at community level. It also stressed the important role
the RBM Vector Control Working Group (VCWG) will
play in helping to ensure VC TEG recommendations are
implemented. It identified that one type of expertise
missing from the VC TEGs membership was social sci-
ence, and that a social scientist must be included as a
core member. WHO-GMP will follow up on this recom-
mendation prior to the first meeting of the VC TEG in
July 2013.
RTS,S/AS01 malaria vaccine
Since its last update to MPAC, the Joint Technical Expert
Group (JTEG) on Malaria Vaccines, jointly convened by
WHO-GMP and the WHO Department of Immunization,
Vaccines and Biologicals (WHO-IVB), met in October2012 to review the second set of results from the Pivotal
Phase 3 trial of RTS,S/AS01, a candidate vaccine devel-
oped in partnership between GlaxoSmithKline (GSK) and
the PATH Malaria Vaccine Initiative (MVI). These results,
since published [31], were also presented in summary to
MPAC by MVI [32].
Depending on the timings of regulatory submission,
malaria vaccine policy recommendations will be made in
late 2015 during a joint session with MPAC and the
Strategic Advisory Group of Experts on Immunization
(SAGE). These recommendations will be based on all
data available up to 2015, including 30 months of
follow-up in two different age cohorts, site-specific effi-
cacy data and 12 months’ follow-up of a booster dose
given 18 months after the primary series. GSK/MVI have
agreed that additional analyses requested by JTEG will
be performed prior to 2015, and will form part of
WHO’s evidence assessment.
JTEG reported that key policy questions include the
duration of protection, whether efficacy varies with trans-
mission intensity, and determining the appropriate age
group and schedule for administration [33]. Although the
original target group was infants aged six, ten, and
14 weeks, the published results raise the possibility of im-
plementation in children aged five to 17 months. If the
protective efficacy is confirmed to be higher in this age
group, it would have operational implications, including
potentially higher delivery costs. It is too early to draw
conclusions about the public health role of RTS,S/AS01.
This vaccine will be evaluated as a potential addition to,
not a replacement for, integrated approaches of existing
preventive, diagnostic and treatment measures tailored to
a given endemic setting [34].
Detailed questions and answers regarding RTS,S/AS01
are available on the WHO website [35].
Malaria vaccine technology roadmap update
MPAC was also updated on the Malaria Vaccine Tech-
nology Roadmap [36,37], which was originally launched
in 2006 and focused at that time on P. falciparum, the
under-five year old age group, and prevention of severe
disease and death. Parts of the 2006 Roadmap are out of
date, and it is currently being revised. The updated ver-
sion includes consideration of both P. falciparum and P.
vivax. The two new strategic goals include firstly, a focus
on clinical disease prevention in endemic areas, and sec-
ondly, on transmission reduction that could potentially
enable elimination in multiple settings if appropriate
vaccines are developed, with a time frame of at least five
to ten years for vaccine development. Two sets of WHO
preferred product characteristics (PPCs) will be devel-
oped in 2013–2014 that will provide technical guidance
for vaccine developers at early stages of vaccine research
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MPAC endorsed the concept of WHO PPCs for mal-
aria vaccines, and recommended that MPAC’s input be
included as the documents are developed, together with
the input of the Strategic Advisory Group of Experts on
Immunization (SAGE).
Financing malaria control
WHO-GMP sought guidance from MPAC on what strat-
egies should be used to allocate limited funds, both glo-
bally between countries and internally within countries
[38]. Although MPAC advises WHO-GMP on the most
effective interventions for malaria control and elimin-
ation, current funding levels do not allow for full imple-
mentation of these interventions globally. It is important
that decisions on resource allocation are based on trans-
parent, clearly defined criteria rather than being driven
by political expediency or by those with the loudest
voice.
The question of global resource allocation primarily
affects international funding for malaria control between
countries. In considering equity and health objectives,
WHO-GMP presented five hypothetical ways, together
with illustrated examples, in which funding for malaria
control could be allocated among countries: (a) allocat-
ing equal amounts of money per person at risk of mal-
aria; (b) allocating funds in order to provide equal access
to interventions; (c) allocating funds according to disease
burden, e.g., in proportion to number of deaths or death
rates; (d) allocating funds to maximize lives saved; and,
(e) allocating funds to equalize health status [39].
For resource allocation within countries, few govern-
ments have sufficient resources to achieve universal cove-
rage of all malaria control interventions (vector control,
diagnostic testing, treatment, surveillance, management
support etc.). As a consequence, they make decisions, in
many cases with little guidance, on what blend of inter-
ventions should be used, their scale of deployment, and
on the populations that should benefit. Of particular rele-
vance are the questions: (a) what interventions should a
country invest in if resources are not sufficient to achieve
universal coverage of vector control, diagnostic testing
and treatment?; and, (b) to which populations should in-
terventions be targeted? Should there be: (i) no targeting,
i.e., all populations at risk get an equal share of resources;
(ii) targeting to highest transmission areas; or, (iii) tar-
geting to demographically vulnerable groups such as preg-
nant women and children?
The advice from MPAC for both funders and countries
was to always use the guiding public health principle of
maximizing health gains to determine how to allocate
limited resources between countries and within coun-
tries. This principle generally implies that financing andinterventions should be targeted to countries and popu-
lations with the highest mortality rates, although targe-
ting could be by geographical area or by vulnerable
groups, or both. MPAC members felt that these options
were not mutually exclusive as long as the guiding prin-
ciple remained the same.
MPAC accepted that in some cases, global funding
politics might interfere with the implementation of this
advice; however it did not change what the guiding
principle should be, from a technical standpoint. MPAC
took great care to stress that maximizing health gains in
countries included the principle of continuing invest-
ments in places where the disease burden has been re-
duced through control measures, but where the intrinsic
malaria transmission potential remains elevated, in order
to avoid malaria resurgence with high mortality and loss
of previous gains.
Malaria surveillance
MPAC considered whether a TEG should be established
on surveillance, monitoring and evaluation (SME TEG).
The SME TEG would develop guidance on what strat-
egies endemic countries can employ to monitor and
evaluate malaria programmes which would include fi-
nancial tracking, programme coverage, disease trends,
and following the advice of the ERG MBE, malaria bur-
den estimation as well [40].
WHO-GMP explained the urgent need for a SME
TEG [41]. The past decade has witnessed tremendous
expansion in the financing and coverage of malaria con-
trol programmes which has led to significant decreases
in malaria cases and deaths [7]. However, while there
has been much progress in programme implementation,
the ability to track programme financing, coverage and
impact remains weak, particularly in countries where
both burden and malaria control investments are grea-
test. For example, out of the 99 countries with ongoing
malaria transmission, 41 were unable to submit suffi-
ciently complete and consistent data to reliably assess
trends in malaria cases. These countries account for 85%
of estimated malaria cases [7].
Weaknesses in surveillance, monitoring and evaluation
stem partly from the fragmented guidance to countries
on how to monitor and evaluate programmes. There has
been progress in the development of such guidance in
the past decade: WHO-GMP released two surveillance
manuals in 2012 [42,43], and the RBM Monitoring and
Evaluation Reference Group (MERG) has worked to
harmonize household survey indictors for ITN coverage,
uptake of IPTp, parasite prevalence and, more recently,
diagnostic testing. However, significant gaps remain,
such as how to monitor the extent of diagnostic testing
and the appropriate use of anti-malarial medicines,
which are key components of the T3: Test. Treat. Track.
Malaria Policy Advisory Committee and Secretariat Malaria Journal 2013, 12:213 Page 7 of 11
http://www.malariajournal.com/content/12/1/213initiative [44] launched by the WHO Director General
in April 2012.
A principal gap is the lack of updated comprehensive
guidance that is specifically useful to NMCP managers
and other national and subnational public health staff.
RBM MERG has made considerable advances in ensur-
ing that approaches used in large surveys are consistent,
but the principal focus has been on deriving information
for international monitoring rather than developing gui-
dance to strengthen national surveillance systems.
MPAC endorsed the creation of a SME TEG, noting
that guidance to countries should be consistent with
WHO recommendations, and there should be no confu-
sion on what the indicators for monitoring programme
coverage should be. Such guidance should be reviewed
on a regular basis, in conjunction with latest MPAC rec-
ommendations or methodological developments, in or-
der to reflect current best practice. WHO-GMP should
work closely with RBM and its working groups to help
ensure that the guidance from the SME TEG is im-
plemented at country level.
WHO-GMP will begin a call for CV of interested ex-
perts, and report on progress in constituting the SME
TEG at the next MPAC meeting in September 2013.
It will also enable a natural handover from the time-
limited ERG on malaria burden estimation to the new
TEG. WHO-GMP will work closely with RBM to ensure
that the SME TEG and the MERG complement and co-
ordinate with each other.
Criteria and classification related to malaria elimination
The purpose of this session was to introduce possible
development of a definition of and criteria for malaria
elimination at the subnational level [45]; these will be
presented for decision at a future MPAC meeting.
While there is mention of the concept of subnational
malaria elimination in some WHO documents, it has
been suggested by WHO Member States and their im-
plementing partners that there is a need for formal
WHO guidance to countries regarding the process of
achieving, maintaining and documenting subnational
elimination. Experience from the Philippines suggests
that: (a) such national processes should emulate WHO
certification; (b) a clear distinction should be made be-
tween the roles of the national authorities and those of
the subnational areas under consideration for malaria-
free status; and, (c) emphasis should be placed on the
capacity of the subnational administrative area to achieve
and maintain malaria-free status with limited central fi-
nancial and technical support. However, this might need
to be applied with flexibility in the case of, for example,
small island provinces.
MPAC concluded that there is a need for WHO guid-
ance to countries about handling subnational elimination,for example at the state and province levels in countries
such as India and China, and requested WHO-GMP to
present a clear proposal at a future meeting. Subnational
elimination targets, should countries choose to pursue
them, could be important internal milestones for coun-
tries, as well as being potentially important international
milestones, especially in larger countries. It was suggested
that at a future meeting, MPAC should review current cri-
teria for WHO certification and discuss the possible need
for a procedure for decertification.
Intermittent preventive treatment in pregnancy
WHO-GMP provided MPAC with a brief update on pro-
gress with its IPTp recommendations [46]. In October
2012, following MPAC recommendations to update the
IPTp-sulphadoxine-pyrimethamine (IPTp-SP) policy to
provide SP at each scheduled antenatal care visit [47],
WHO published the recommendation and urged na-
tional health authorities to disseminate it widely and to
ensure its correct application. Based on initial feedback
from national programmes and implementing partners,
WHO-GMP and the WHO Reproductive Health and
Research Department (WHO-RHR) developed a policy
briefing paper to offer additional background informa-
tion, more explanations on operational aspects, a com-
pilation of the scientific evidence, and a set of frequently
asked questions on IPTp-SP [48].
WHO-GMP reported that new evidence will be avail-
able for review by the ERG IPTp in July 2013, including
results from: (a) a series of IPTp-SP studies by the Mal-
aria in Pregnancy Consortium (MIPc) and the US Presi-
dent’s Malaria Initiative (PMI) evaluating the association
between SP resistance and IPTp-SP effectiveness; and,
(b) two randomized clinical trials on the efficacy and
safety of mefloquine for IPTp, in the context of ITNs.
In addition, simplified protocols are being developed
to monitor the potential impact of SP resistance on
IPTp-SP effectiveness and to monitor the programmatic
determinants of IPTp-SP effectiveness.
The ERG IPTp will reconvene in July 2013 to: (a)
review the evidence regarding the contribution of SP re-
sistance to IPTp effectiveness; (b) finalize the core proto-
col to monitor the impact of SP resistance on IPTp-SP
effectiveness; (c) review evidence on the efficacy and
safety of mefloquine for IPTp compared to SP (for all
women) and to daily co-trimoxazole prophylaxis (for
HIV + pregnant women); and, (d) develop draft policy
recommendations on the contribution of SP resistance
to IPTp effectiveness and monitoring methods, as well
as on the efficacy and safety of mefloquine for IPTp for
consideration by the MPAC in September 2013.
Because of the safety concerns related to the use of
mefloquine, MPAC urged WHO-GMP to undertake a
safety review of this drug with particular reference to its
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the recommendations for its use for chemoprophylaxis
in the next (third) edition of the WHO Guidelines for
the Treatment of Malaria [49].
Elimination scenario planning toolkit
An Elimination Scenario Planning (ESP) toolkit is cur-
rently in the process of being finalized after being field
tested using data from The Gambia and Senegal in 2012,
and will be released online, with an accompanying man-
ual, in the next few months. WHO-GMP updated the
MPAC on the ESP toolkit, and requested advice on po-
tential new directions following its initial release [50,51].
The ESP toolkit, developed by WHO-GMP with part-
ners from the Clinton Health Access Initiative (CHAI),
Imperial College London, and the Global Health Group
at the University of California San Francisco (GHG/
UCSF), covers the technical, operational and financial
aspects of malaria elimination, and provides realistic
timelines for programmes moving from the control to
the elimination phase of malaria programme operations.
The toolkit includes a manual that reviews elimination
concepts and guides users through the feasibility of mal-
aria elimination. The manual is linked to software that
models malaria transmission, currently limited to P. fal-
ciparum in Africa, which allows users to explore the
effect of a range of combinations of malaria control in-
terventions in order to achieve elimination. Feedback
from field testing by malaria control programme staff
and researchers from The Gambia and Senegal has been
positive.
During the development of the toolkit, WHO-GMP
and partners recognized that a similar approach could
be used for malaria programme planning in other
settings. WHO-GMP sought advice from MPAC on: (a)
whether the ESP toolkit should be modified to function
as a general programme planning tool; (b) whether it
should be extended to address scenarios of low trans-
mission P. falciparum outside of Africa; and, (c) whether
it should be extended to cover settings where P. vivax is
predominant.
Although at present the toolkit is focused on planning
for potential elimination scenarios, many of the concepts
covered in the manual regarding technical and oper-
ational aspects of implementing interventions, including
the transmission software itself, are applicable to coun-
tries that have near-term goals other than elimination.
With a steadily growing list of intervention tools, one
aspect of the software that countries in the control
programme phase may find useful is the ability to ex-
plore combinations of interventions, and their projected
cost. MPAC members welcomed this development, and
were broadly supportive of extending the toolkit, par-
ticularly for P. falciparum outside Africa, but felt thatthis should not be rushed. For example, extending the
toolkit for P. vivax settings would be in line with the
current work of WHO-GMP in the development of a P.
vivax strategy, and could be timed for release at the
same time.
In general, MPAC members welcomed the develop-
ment of the ESP toolkit that NMCPs could use to add
rigour to programme goal setting and policy develop-
ment, as well as in planning and budgeting for interven-
tions. This view was supported by the NMCP managers,
and WHO Regional Malaria Advisors present at the
meeting.
Global technical strategy (2016–2025)
WHO-GMP provided an update to MPAC on progress
since its last meeting where members called for an over-
arching review of the malaria strategy mix to underpin
planned revisions to the Global Malaria Action Plan
(GMAP) [52]. After a brief historical perspective – the
last Global Strategy for malaria was launched in 1993
and was a highly time- and resource-intensive process –
WHO-GMP outlined some of the key issues it is grap-
pling with as it moves forward with the Global Technical
Strategy 2016–2025 (GTS) [53].
One of these is timing, since a policy recommendation
on the RTS,S vaccine will not be made until late 2015, at
the earliest. Although seeking formal World Health As-
sembly (WHA) endorsement of the GTS will increase
the engagement of Member States and elevate the polit-
ical profile of the strategy, it will also have implications
on the timing for developing, finalizing and launching
the GTS. The process for country and regional con-
sultation in developing the GTS was discussed. Broad
endemic country input is critical. However, it is not feas-
ible or efficient to replicate the lengthy and costly pro-
cess used to develop the last global strategy. Moreover,
there are already many region-specific strategies. WHO-
GMP also highlighted the importance of working closely
with RBM to harmonize the development of the GTS
and the update of the GMAP.
The MPAC provided guidance on how to address
these issues. It felt strongly that the timing for develop-
ing the GTS should not be bound by the anticipated rec-
ommendation for the RTS,S vaccine in 2015. There will
be multiple new tools on the horizon; their development
should be included, but guidance will need to be pro-
vided as the evidence emerges for any new tools or ap-
proaches. Members envisioned that the GTS should be a
living document – a clear and concise technical strategy
that can be updated as necessary and adapted for re-
gional and national use to produce more detailed imple-
mentation plans that are relevant to the local context.
This is one reason why it will be extremely important to
engage regional and national experts in developing the
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other global strategies, specifically the Global Vaccine
Action Plan, included using a combination of web con-
sultations and add-ons to already scheduled regional and
national meetings in order to seek input.
MPAC recommended that the GTS be put forward to
the sixty eighth session of the WHA in 2015 for en-
dorsement. It also suggested that the GTS and GMAP
be developed in a collaborative process, and be launched
together as companion documents in the second half of
2015. One possible way that might help this process was
to have some overlap in the GTS and GMAP Steering
Committees.
MPAC advised that WHO-GMP establish an internal
working group to help lead the process under the advice
of MPAC and a Steering Committee. This working
group will develop an initial draft of the GTS prior to
seeking broader consultation from regions and counties.
Discussion
The wording for recommendations was finalized by
MPAC during their closed session following the two-and-
a-half days of open sessions; conclusions have been in-
cluded in the summaries of the meeting sessions above,
and links to the full set of meeting documents have been
provided as references.
Position statements and policy recommendations made
by the MPAC are approved by the WHO Director-
General, and will be formally issued and disseminated to
WHO Member States by WHO-GMP or if more appro-
priate, the WHO Regional Offices. Conclusions and rec-
ommendations from MPAC meetings are published in the
Malaria Journal as part of this series.
MPAC provided suggestions for the agenda for its next
meeting to the WHO-GMP Secretariat. Feedback will
also be given to and received from the global malaria
community at the RBM Board meeting in May 2013,
and through the publication of and correspondence re-
garding this article.
Ongoing engagement with and attendance by inter-
ested stakeholders at MPAC meetings continues to be
encouraged. In addition to open registration for MPAC
meetings, which will continue (via the WHO-GMP web-
site starting in July) and attendance by four standing ob-
servers (RBM, the Global Fund, UNICEF, Office of the
UN Special Envoy for malaria), the active participation
of seven rotating NMCP representatives, and all six WHO
Regional Malaria Advisors, was strongly welcomed.
Conclusion
The meeting feedback received from participants and
observers [54], and MPAC members themselves, was
very positive. Having met three times to date, the format
of MPAC meetings and its feedback loops with otheradvisory bodies and stakeholders is beginning to settle,
although it remains an evolving process. WHO-GMP
and the MPAC continue to strongly welcome feedback,
support and suggestions for improvement to MPAC
meetings from the global malaria community.
The next meeting of the MPAC will take place from
11 to 13 September 2013 in Geneva, Switzerland. Fur-
ther information, including the agenda and details on
how to register, will be made available in July 2013 on
the MPAC page of the WHO-GMP website, although
questions are welcome at any time [5].
Endnotes
a The complete set of all MPAC March 2013 meeting-
related documents including background papers, presen-
tations, and member declarations of interest can be found
online at http://www.who.int/malaria/mpac/mar2013/en/
index.html.
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